GlassScriptPhysician profile
Richard Idell
NPI 1437474889
$8,881.16
in general payments reported to CMS, 2019-2025
33 companies · $3,496 in 2025
The $3,496 reported for 2025 was more than what 93% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.60 · 2021: $24.31 · 2022: $1,028 · 2023: $1,914 · 2024: $2,399 · 2025: $3,496.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,809.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,136.94 | 2019-2025 | Rexulti, Nuedexta, Abilify Asimtufii |
| Corium, LLC | $1,017.94 | 2022-2025 | Azstarys, Azstarys |
| Neurocrine Biosciences, INC. | $958.69 | 2021-2025 | Ingrezza |
| Validus Pharmaceuticals LLC | $663.07 | 2022-2025 | Equetro, Equetro, Raldesy |
| Lundbeck LLC | $650.98 | 2022-2025 | Rexulti, Brintellix |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $641.48 | 2022-2025 | Caplyta |
| Alkermes, INC. | $548.62 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $514.54 | 2023-2025 | |
| Almatica Pharma LLC | $332.84 | 2022-2025 | Loreev Xr |
| Vanda Pharmaceuticals INC. | $318.93 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $254.05 | 2022-2025 | Auvelity |
| Idorsia Pharmaceuticals US INC | $206.66 | 2022-2024 | Quviviq |
| Tris Pharma INC | $189.50 | 2022-2024 | Dyanavel Xr |
| Teva Pharmaceuticals USA, INC. | $183.58 | 2023-2025 | Austedo Xr, Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $152.70 | 2025 | Cobenfy |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $132.47 | 2022-2025 | Spravato, Invega Trinza, Invega Sustenna |
| Merck Sharp & Dohme LLC | $110.56 | 2022-2023 | Belsomra |
| Takeda Pharmaceuticals U.S.A., INC. | $107.84 | 2022-2024 | Trintellix |
| Neos Therapeutics, LP | $106.51 | 2022-2025 | Adzenys Xr-Odt |
| Supernus Pharmaceuticals, INC. | $105.18 | 2022-2023 | Qelbree |
| Bausch Health US, LLC | $103.92 | 2023-2025 | Aplenzin, Wellbutrin |
| Noven Therapeutics, LLC | $89.96 | 2023-2025 | Secuado, Xelstrym |
| Acadia Pharmaceuticals INC | $84.26 | 2022-2024 | Nuplazid |
| Vertical Pharmaceuticals, LLC | $50.56 | 2025 | Relexxii |
| Avanir Pharmaceuticals, INC. | $49.42 | 2022 | |
| Livanova USA, INC. | $30.88 | 2025 | Vns Therapy Symmetry Model 8103 Generator |
| Jazz Pharmaceuticals INC. | $28.33 | 2023 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $26.60 | 2025 | Rejoyn |
| Sunovion Pharmaceuticals INC. | $23.45 | 2022 | |
| Harmony Biosciences LLC | $17.95 | 2024 | |
| Collegium Pharmaceutical, INC. | $15.12 | 2025 | Jornay Pm |
| Lilly USA, LLC | $13.85 | 2025 | Zepbound |
| Ironshore Pharmaceuticals INC. | $13.78 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Idell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.